Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...

Veeral S. Sheth, MD, MBA, FACS, FASRS, on how the avacincaptad pegol label update, earlier treatment, and patient counseling shape long-term GA care.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2024, Healio covered several stories about trials ...

Lakhanpal said his first goal with a newly diagnosed patient is to confirm the diagnosis and talk about GA in general. He ...

In this Healio video, Roger A. Goldberg, MD, discusses 5-year outcomes of pegcetacoplan for the treatment of geographic atrophy. Data from the GALE extension study, presented at the Macula Society ...

Over 24 months, dosing with monthly avacincaptad pegol resulted in a statistically significant year-over-year reduction of 14% in the mean rate of GA growth vs sham. The Food and Drug Administration ...

The earlier patients with potentially blinding geographic atrophy start treatment with the complement inhibitor pegcetacoplan, the more retinal tissue they retain 4 years later compared with patients ...

A mixed-logit analysis showed lesion growth rate reduction drove choice (40.9%-52.1% RAI), especially for foveal-threatening lesions and poor visual acuity in the unaffected eye. Conversion to wet AMD ...

TOKYO, May 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), maker of IZERVAY™ (avacincaptad pegol intravitreal solution), a C5 inhibitor for the ...

Geographic atrophy (GA) progressed more often in patients with better baseline vision and those with lesions closer to the foveal center, according to a study that could help provide needed treatment ...

Geographic atrophy (GA) is an advanced form of dry macular degeneration that causes irreversible vision loss and affects daily activities such as reading, driving, and recognizing faces. Vision loss ...